Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 11, Issue 3, 2004, Pages 169-183

  Paciotti, Giulio F ^a   Myer, Lonnie ^a   Weinreich, David ^b   Goia, Dan ^c   Pavel, Nicolae ^d   McLaughlin, Richard E ^c   Tamarkin, Lawrence ^a  

^a CytImmune Sciences Inc   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OMG dmc2   (United States)

^d Ferro Corporation   (United States)

Author keywords

Colloidal Gold; Drug Delivery; Tumor Necrosis Factor

Indexed keywords

COLLOIDAL GOLD; GOLD; NANOCARRIER; NANOPARTICLE; RECOMBINANT TUMOR NECROSIS FACTOR; THIOL DERIVATIVE; THIOL DERIVATIZED MACROGOL COLLOIDAL GOLD TUMOR NECROSIS FACTOR COMPLEX; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; SOLID TUMOR; SPLEEN; TUMOR DIRECTED DRUG DELIVERY SYSTEM; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GOLD COLLOID; HYDROGEN-ION CONCENTRATION; INDICATORS AND REAGENTS; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; MICROSPHERES; NEOPLASM TRANSPLANTATION; NEOPLASMS; PARTICLE SIZE; PLATINUM; RETICULOENDOTHELIAL SYSTEM; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2642535307     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/10717540490433895     Document Type: Article

References (42)

1. Alexander, H. R., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., and Rosenberg, S. A. 1998. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16:1479-1489.
2. Baban, D. F. 1998. Control of tumour vascular permeability. Ad. Drug Delivery Rev. 34:109-119.
3. Bergqvist, L., Sundberg, R., Ryden, S., and Strand, S. E. 1987. The "critical colloid dose" in studies of reticuloendothelial function. J. Nucl. Med. 28:1424-1429.
4. Bradfield, J. W. 1980. A new look at reticuloendothelial blockade. Br. J. Exp. Pathol. 61:617-623.
5. Chandler, J., Robinson, N., and Whiting, K. 2001. Handling false signals in gold-based tests. I.V.D. Technol. 72 (2001):34-35.
6. Cleland, J. L. 1997. Protein delivery from biodegradable microspheres. In Protein Delivery: Physical Systems, eds. Sanders and Hendren, 1-43. New York: Plenum Press.
7. Creaven, P. J., Plager, J. E., Dupere, S., Huben, R. P., Takite, H., Mittleman, A., and Proefrock, A. 1987. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 20:137-144.
8. Faraday, M. 1857. Experimental relations of gold (and other metals) to light. Philos. Trans. R. Soc. London 14:145-181.
9. Fraker, D. L., Alexander, H. R., Andrich, M., and Rosenberg, S. A. 1996. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 14:479-489.
10. Frens, G. 1972. Controlled nucleation for the regulation of particle size in monodisperse gold suspensions. Nature Phys. Sci. 241:20-22.
11. Furman, W. I., Strother, D., McClain, K., Bell, B., Leventhol, B., and Pratt, C. B. 1993. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A pediatric oncology group study. J. Clin. Oncol. 11:2205-2210.
12. Hardonk, M. J., Harms, G., and Koudstaal, J. 1985. Zonal heterogeneity of rat hepatocytes in the vivo uptake of 17 nm colloidal gold granules. Histochemistry 83:473-477.
13. Hermanson, G. T. 1996. Bioconjugate Techniques. Academic Press, Inc., San Diego, California.
14. Horisberger, M. 1979. Evaluation of colloidal gold as a cytochemical marker for transmission and scanning electron microscopy. Biol. Cellulaire 36:253-258.
15. Illum, L., Davis, S. S., Muller, R. H., Mak, E., and West, P. 1987. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-poloxamine 908. Life Sci. 40:367-374.
16. Jain, R., Shah, N. H., Malick, A. W., and Rhodes, C. T. 1998. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev. Indust. Pharm. 24:703-727.
17. Kristensen, C. A., Nozue, M., Boucher, Y., and Jain, R. K. 1996. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J. Cancer 74:533-536.
18. Kurfurst, M. 1992. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 200:244-248.
19. Lejeune, F. J. 1995. High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumors of the limbs: a model for biochemotherapy of cancer. Eur. J. Cancer 3:1009-1016.
20. Maruyama, K., Takizawa, T., Takahashi, N., Tagawa, T., Nagaike, K., and Iwatsuru, M. 1998. Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Ad. Drug Delivery Rev. 24:235-242.
21. Maruyama, K., Ishida, O., Takizawa, T., and Moribe, K. 1999. Possibility of active targeting to tumor tissues with liposomes. Ad. Drug Delivery Rev. 40:89-102.
22. Mirkin, C. A., Letsinger, R. L., Mucic, R. C., and Storhoff, J. J. 1996. A DNA based method for rationally assembling nanoparticles into macroscopic materials. Nature 382:607-609.
23. Moghimi, S. M. 1999. Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. Biochim. Biophys. Acta 1472:399-403.
24. Moghimi, S. M., and Patel, H. M. 1998. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Ad. Drug Delivery Rev. 32:45-60.
25. Molema, G., de Leij, L. F. M. H., and Meijer, D. K. F. 1997. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 14:2-38.
26. Müller, R. H., Mäder, K., and Gohla, S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur. J. Pharm. Biopharm. 50:161-177.
27. Nafayasu, A., Uchiyama, K., and Kiwada, H. 1999. The size of liposomes: a factor, which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Ad. Drug 40:75-87.
28. Nedrebo, T., Berg, A., and Reed, R. K. 1999. Effect of tumor necrosis factor-α, IL-1-β, and IL-6 on interstitial fluid pressure in rat skin. Am. J. Physiol. 277 Heart Circ. Physiol. 46:H1857-H1862.
29. Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstia, D., Graham, W., Hunter, G. J., Wolf, G. L., Fischnan, A., Boucher, Y., and Jain, R. K. 1999. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA 96:3137-3142.
30. Nuzzo, R. G., and Allara, D. L. 1983. Adsorption of Bifunctional Organic Disulfides on Gold Surfaces. J. Am. Chem. Soc. 105:4481-4483.
31. Ogawa, Y. 1997. Injectable microcapsules prepared with biodegradable poly(α-hydroxy) acids for prolonged release of drugs. J. Biomater. Sci. Polymer Edn. 8:391-409.
32. Papisov, M. I. 1998. Theoretical considerations of RES-avoiding liposomes: molecular mechanisms and chemistry of liposome interactions. Ad. Drug Delivery Rev. 32:119-138.
33. Rafferty, D. E., Elfaki, M. G., and Montgomery, P. C. 1996. Preparation and characterization of a biodegradable microparticle antigen/cytokine delivery system. Vaccine 14:532-538.
34. Redhead, H. M., Davis, S. S., and Illum, L. 2001. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Control Release 70:353-363.
35. Renaud, G., Hamilton, R. L., and Havel, R. 1989. Hepatic metabolism of colloidal gold-low-density lipoprotein complexes in the rat: evidence for bulk excretion of lyosomal contents into bile. Hepatology 9:380-392.
36. Root, S. W., Andrews, G. A., Knieseley, R. M., and Tyor, M. P. 1954. The distribution and radiation effects of intravenously administered colloidal Au 198 in man. Cancer 7:856-866.
37. Rubin, P., and Levitt, S. H. 1964. The response of disseminated reticulum cell sarcoma to the intravenous injection of colloidal radioactive gold. J. Nuclear Med. 5:581-594.
38. Schiller, J. H., Storer, B. E., Witt, P. L., Alberti, D., Tombes, M. M. B., Arzoomanian, R., Proctor, R. A., McCarthy, D., Brown R. R., Voss, S. D., Remick, S. C., Grem, J. L., Borden, E. C., and Trump, D. L. 1991. Biological and clinical effects of intravenous tumor necrosis factor-a administered three times weekly. Cancer Res. 51:1651-1658.
39. Stohrer, M., Boucher, Y., Stangassinger, M., and Jain, R. K. 2000. Oncotic pressure in solid tumors is elevated. Cancer Res. 60:4251-4255.
40. Taguchi, T. 1988. Phase I study of recombinant human tumor necrosis factor (rHuTNF-PT-050). Cancer Detect. Prev. 12:561-572.
41. Woodle, M. C. 1998. Controlling liposome blood clearance by surface grafted polymers. Ad. Drug Delivery Rev. 32:139-152.
42. Zhang, X. Y., Luck, J., Derhirst, M. W., and Fan Yuan, F. 2000. Interstitial hydraulic conductivity in a fibrosarcoma. Am. J. Physiol. Heart Circ. Physiol. 279:H2726-H2734.